EPIRUS Biopharma (EPRS) Tops Q4 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
EPIRUS Biopharmaceuticals (EPRS) PT Raised to $13 at Leerink Partners
March 25, 2015 6:19 AM EDTLeerink Partners analyst Jason Gerberry reiterated an Outperform rating and boosted his price target on EPIRUS Biopharmaceuticals (NASDAQ: EPRS) to $13.00 (from $10.00) saying the pipeline is on track and the company has a cash runway into 2016.
Gerberry commented, "This morning EPRS provided several... More
